← 產業報告目錄
China Small Molecule CDMO Market Size, Share & Trends Analysis Report By Product (Active Pharmaceutical Ingredients (API), Finished Drug Products), By Drug (Innovators, Generics), By Application (Cardiovascular Disease), and Segment Forecasts, 2026 - 2033
出版商 Grand View Research產業別 Medical Devices出版日期 2026-06-01頁數 120報告編號 GVR-4-68040-031-0
授權報價
| Single User License | $5,950 USD |
| Enterprise License | $6,950 USD |
| Corporate User License | $8,950 USD |
報告摘要
China Small Molecule CDMO Market Summary
The China small molecule CDMO market size was valued at USD 4.6 billion in 2025 and is projected to grow from USD 5.0 billion in 2026 to USD 9.4 billion by 2033, at a CAGR of 9.6% from 2026 to 2033. The market growth is driven by rising drug discovery efforts in fields like oncology, cardiovascular, and the central nervous system, which has led many pharmaceutical companies to turn to outsourcing.
Besides, the small-molecule CDMOs in China are characterized by favorable cost structures, a skilled workforce, and a growing range of domestic projects, making them an appealing partner for both local and international companies. In addition, the market's expansion is driven by rising demand for generics and innovative small-molecule therapies, further fueling the trend toward integrated, end-to-end development and manufacturing solutions.
In addition, technological advancements in the market have played a crucial role in enhancing the capabilities of China's CDMO sector, further supporting market growth. Besides, innovations such as process optimization, real-time monitoring via Process Analytical Technology (PAT), and machine learning applications for predictive analytics are increasingly prioritized to improve efficiency and product quality. Moreover, the integration of continuous manufacturing technologies and advanced synthetic chemistry further supports the development of high-potency and complex molecules. This technological advancement has further supported the Chinese CDMOs to compete more effectively in the global arena, particularly for early-phase and high-value niche projects.
Furthermore, increased investments are being made to drive small molecule CDMO capabilities, supported by government initiatives like "Made in China 2025," which has fueled the Chinese small molecule CDMO facilities in key locations such as Shanghai, Suzhou, and Hangzhou. These investments are enhanced by venture capital and international collaborations. Numerous partnerships and licensing agreements between multinational pharmaceutical companies and local biotechs are reinforcing the domestic CDMO pipeline. Moreover, upgrades to facilities to comply with Good Manufacturing Practices (GMP) and strategic acquisitions are also underway to improve global competitiveness.
China Small Molecule CDMO Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the China small molecule CDMO market report based on product, drug, and application:
• Product Outlook (Revenue, USD Billion, 2021 - 2033)
o Active Pharmaceutical Ingredients (API)
o Finished Drug Products
• Drug Outlook (Revenue, USD Billion, 2021 - 2033)
o Innovators
o Generics
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
o Oncology
o Cardiovascular Disease
o Central Nervous System (CNS) Conditions
o Autoimmune/Inflammation
o Others
目錄 Table of Contents
Table of Contents
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Drug
1.2.3. Application
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Bottom-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. China Small Molecule CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rise In Drug Development Pipelines
3.2.1.2. Growing Reliance on CDMOs for Cost-Effective and Specialized Manufacturing Services
3.2.1.3. Capacity Expansion by CDMOs
3.2.1.4. Technological Advancements
3.2.2. Market Restraint Analysis
3.2.2.1. Growing Demand for Biologics
3.2.2.2. Complexity and Challenges in the Synthesis of Certain Small Molecules, Impacting Manufacturing Efficiency
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter’s Five Force Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. China Small Molecule CDMO Market: Product Estimates & Trend Analysis
4.1. China Small Molecule CDMO Market, By Product: Segment Dashboard
4.2. China Small Molecule CDMO Market, By Product: Movement Analysis
4.3. China Small Molecule CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
4.4. Active Pharmaceutical Ingredients (API)
4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.5. Finished Drug Products
4.5.1. Finished Drug Products Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. China Small Molecule CDMO Market: Drug Estimates & Trend Analysis
5.1. China Small Molecule CDMO Market, By Drug: Segment Dashboard
5.2. China Small Molecule CDMO Market, By Drug: Movement Analysis
5.3. China Small Molecule CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Billion)
5.4. Innovators
5.4.1. Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.5. Generics
5.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. China Small Molecule CDMO Market: Application Estimates & Trend Analysis
6.1. China Small Molecule CDMO Market, By Application: Segment Dashboard
6.2. China Small Molecule CDMO Market, By Application: Movement Analysis
6.3. China Small Molecule CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Billion)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.5. Cardiovascular Disease
6.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.6. Central Nervous System (CNS) Conditions
6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.7. Autoimmune/Inflammation
6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. Competitive Landscape
7.1. Key Participant Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
7.3. Company Profiles
7.3.1. Lonza
7.3.1.1. Company Overview
7.3.1.2. Financial Performance
7.3.1.3. Service Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Catalent, Inc.
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Service Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Thermo Fisher Scientific Inc.
7.3.3.1. Company Overview
7.3.3.2. Financial Performance
7.3.3.3. Service Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Bellen Chemistry
7.3.4.1. Company Overview
7.3.4.2. Financial Performance
7.3.4.3. Service Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Siegfried Holding AG
7.3.5.1. Company Overview
7.3.5.2. Financial Performance
7.3.5.3. Service Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Recipharm AB
7.3.6.1. Company Overview
7.3.6.2. Financial Performance
7.3.6.3. Service Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. WuXi AppTec
7.3.7.1. Company Overview
7.3.7.2. Financial Performance
7.3.7.3. Service Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Asymchem Laboratories
7.3.8.1. Company Overview
7.3.8.2. Financial Performance
7.3.8.3. Service Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. Langhua Pharmaceutical (Viva Biotech subsidiary)
7.3.9.1. Company Overview
7.3.9.2. Financial Performance
7.3.9.3. Service Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Apeloa Pharmaceutical
7.3.10.1. Company Overview
7.3.10.2. Financial Performance
7.3.10.3. Service Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. JiuZhou Pharmaceutical
7.3.11.1. Company Overview
7.3.11.2. Financial Performance
7.3.11.3. Service Benchmarking
7.3.11.4. Strategic Initiatives
圖表清單 List of Tables & Figures
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 China Small Molecule CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Billion)
Table 4 China Small Molecule CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Billion)
Table 5 China Small Molecule CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Billion)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD model sizing & forecasting
Fig. 9 Bottom-up approach
Fig. 10 Market snapshot
Fig. 11 Segment snapshot 1
Fig. 12 Segment snapshot 2
Fig. 13 Competitive landscape snapshot
Fig. 14 Parent market outlook, 2025 (USD Billion)
Fig. 15 Ancillary market outlook, 2025 (USD Billion)
Fig. 16 China Small Molecule CDMO Market Dynamics
Fig. 17 Porter’s five force analysis
Fig. 18 PESTEL analysis
Fig. 19 China Small Molecule CDMO Market: Product outlook key takeaways
Fig. 20 China Small Molecule CDMO Market: Product movement analysis
Fig. 21 Active Pharmaceutical Ingredients (API) market estimates and forecasts, 2021 - 2033 (USD Billion)
Fig. 22 Finished Drug Products market estimates and forecasts, 2021 - 2033 (USD Billion)
Fig. 23 China Small Molecule CDMO Market: Drug outlook key takeaways
Fig. 24 China Small Molecule CDMO Market: Drug movement analysis
Fig. 25 Innovators Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 26 Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 27 China Small Molecule CDMO Market: Application outlook key takeaways
Fig. 28 China Small Molecule CDMO Market: Application movement analysis
Fig. 29 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 30 Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 31 Central Nervous System (CNS) Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 32 Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
提及公司
LonzaCatalent, IncThermo Fisher Scientific Inc.Bellen ChemistrySiegfried Holding AGRecipharm ABWuXi AppTecAsymchem LaboratoriesLanghua Pharmaceutical (Viva Biotech subsidiary)Apeloa PharmaceuticalJiuZhou Pharmaceutical
量子訊息有限公司為 Grand View Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們